MCM
CUE icon

MAI Capital Management’s Cue Biopharma CUE Stock Holding History

MAI Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$81 – 2658
2026
Q1 		$81 Hold
12
– – ﹤0.01% 4794
2025
Q4 		$107 Hold
12
– – ﹤0.01% 4157
2025
Q3 		$252 Hold
12
– – ﹤0.01% 3686
2025
Q2 		$239 Hold
12
– – ﹤0.01% 3851
2025
Q1 		$319 Hold
12
– – ﹤0.01% 3273
2024
Q4 		$382 Buy
+12
New +$451 ﹤0.01% 3321

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

MAI Capital Management's CUE Position: Q2 2026 in Review

MAI Capital Management sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 12 shares — an estimated $81 sold.

MAI Capital Management first reported a position in CUE in Q4 2024 and held it in 6 quarters. The position peaked at $382 in Q4 2024. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • MAI Capital Management reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 12 Cue Biopharma shares in Q2 2026, an estimated $81.
  • MAI Capital Management first reported a position in Cue Biopharma in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Cue Biopharma position peaked at $382 in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.